Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors

Oncogene

Volumn 33, Issue 22, 2014, Pages 2928-2937

  Tolani, B ^a   Gopalakrishnan, R ^a   Punj, V ^a   Matta, H ^a   Chaudhary, P M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

BET; bromodomain; KSHV; Myc; PEL

Indexed keywords

ANTINEOPLASTIC AGENT; BET BROMODOMAIN INHIBITOR; I BET 151; JQ 1; MYC PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BRD4 GENE; CANCER CELL LINE; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DRUG TARGETING; ENHANCER REGION; GENE LOCUS; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENOME; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; MOUSE; NONHUMAN; ONCOGENE MYC; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROMOTER REGION; RETROVIRUS; SENESCENCE; TRANSLATION REGULATION; TUMOR XENOGRAFT;

HERPESVIRIDAE; HUMAN HERPESVIRUS 8;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZEPINES; CELL AGING; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 8, HUMAN; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; INHIBITORY CONCENTRATION 50; LYMPHOMA, PRIMARY EFFUSION; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRIAZOLES; TUMOR BURDEN; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901842119     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.242     Document Type: Article

References (38)

1. Morris K. Cancer? In Africa? Lancet Oncol 2003; 4: 5. (Pubitemid 36124179)
2. Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int J Cancer 1993; 54: 26-36. (Pubitemid 23136995)
3. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88: 645-656. (Pubitemid 26240396)
4. Boulanger E, Daniel MT, Agbalika F, Oksenhendler E. Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol 2003; 73: 143-148. (Pubitemid 36753954)
5. Boulanger E, Hermine O, Fermand JP, Radford-Weiss I, Brousse N, Meignin V et al. Human herpesvirus 8 (HHV-8)-associated peritoneal primary effusion lymphoma (PEL) in two HIV-negative elderly patients. Am J Hematol 2004; 76: 88-91. (Pubitemid 38579548)
6. Wu SY, Chiang CM. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 2007; 282: 13141-13145.
7. Chung CW, Witherington J. Progress in the discovery of small-molecule inhibitors of bromodomain-histone interactions. J Biomol Screen 2011; 16: 1170-1185.
8. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodo-main inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
9. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
10. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011; 478: 529-533.
11. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T et al. BET bromodomain inhibition targets both c-MYC and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012; 120: 2843-2852.
12. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O et al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-1073.
13. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010; 468: 1119-1123.
14. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011; 108: 16669-16674.
15. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013; 153: 320-334.
16. Li X, Chen S, Feng J, Deng H, Sun R. Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency. J Virol 2010; 84: 8945-8948.
17. Bubman D, Guasparri I, Cesarman E. Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene 2007; 26: 4979-4986. (Pubitemid 47172646)
18. Liu J, Martin HJ, Liao G, Hayward SD. The Kaposi sarcoma associated herpesvirus lana protein stabilizes and activates c-Myc. J Virol 2007; 81: 10451-10459. (Pubitemid 47463318)
19. Lubyova B, Kellum MJ, Frisancho JA, Pitha PM. Stimulation of c-Myc transcriptional activity by vIRF-3 of Kaposi sarcoma-associated herpesvirus. J Biol Chem 2007; 282: 31944-31953. (Pubitemid 350106417)
20. Bhatt S, Ashlock B, Natkunam Y, Ramos JC, Mesri EA, Lossos IS. Preclinical Activity of Brentuximab Vedotin (SGN-35) in primary effusion lymphoma (PEL); 53rd ASH Annual Meeting and Exposition; San Diego, CA, USA, 2011.
21. Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, Blasini W et al. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc Natl Acad Sci USA. 2010; 107: 13069-13074.
22. Zhao H, Darzynkiewicz Z. Biomarkers of cell senescence assessed by imaging cytometry. Methods Mol Biol 2013; 965: 83-92.
23. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550. (Pubitemid 41528093)
24. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 2003; 100: 8164-8169. (Pubitemid 36842516)
25. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J et al. Genomic targets of the human c-Myc protein. Genes Dev 2003; 17: 1115-1129. (Pubitemid 36534986)
26. Nakamura H, Lu M, Gwack Y, Souvlis J, Zeichner SL, Jung JU. Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. J Virol 2003; 77: 4205-4220. (Pubitemid 36350959)
27. Zhao J, Punj V, Matta H, Mazzacurati L, Schamus S, Yang Y et al. K13 Blocks KSHV Lytic Replication and Deregulates vIL6 and hIL6 Expression: a Model of Lytic Replication Induced Clonal Selection in Viral Oncogenesis. PLoS One 2007; 2: e1067.
28. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009; 15: 6479-6483.
29. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2: 764-776. (Pubitemid 37328911)
30. Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA. 2000; 97: 228-233. (Pubitemid 30055813)
31. Ballestas ME, Kaye KM. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA. J Virol 2001; 75: 3250-3258. (Pubitemid 32225888)
32. Garber AC, Hu J, Renne R. Latency-associated nuclear antigen (LANA) cooperatively binds to two sites within the terminal repeat, and both sites contribute to the ability of LANA to suppress transcription and to facilitate DNA replication. J Biol Chem 2002; 277: 27401-27411. (Pubitemid 34951761)
33. You J, Srinivasan V, Denis GV, Harrington Jr. WJ, Ballestas ME, Kaye KM et al. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes. J Virol 2006; 80: 8909-8919. (Pubitemid 44359965)
34. Ottinger M, Christalla T, Nathan K, Brinkmann MM, Viejo-Borbolla A, Schulz TF. Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4-and BRD2/RING3-induced G1 cell cycle arrest. J Virol 2006; 80: 10772-10786. (Pubitemid 44628923)
35. Nicholas J. Human herpesvirus 8-encoded proteins with potential roles in virus-associated neoplasia. Front Biosci 2007; 12: 265-281. (Pubitemid 46860211)
36. Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM. BET bromodomain inhibition activates transcription via a transient release of P-TEFb from 7SK snRNP. J Biol Chem 2012; 287: 36609-36616.
37. Zhu X, Santat LA, Chang MS, Liu J, Zavzavadjian JR, Wall EA et al. A versatile approach to multiple gene RNA interference using microRNA-based short hairpin RNAs. BMC Mol Biol 2007; 8: 98.
38. Shin KJ, Wall EA, Zavzavadjian JR, Santat LA, Liu J, Hwang JI et al. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc Natl Acad Sci USA 2006; 103: 13759-13764. (Pubitemid 44413981)